NY-CANVA
17.6.2024 07:01:32 CEST | Business Wire | Press release
Canva, the world’s only all-in-one visual communication platform, and MMA Global, the leading global trade association for marketers, today released joint research on the value of creative output, tech stack saturation and navigating talent wars.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240616737948/en/
Creative Output is the New Gold Standard (Graphic: Business Wire)
Canva and the MMA surveyed nearly 100 CMOs and senior marketers in decision-making roles from the U.S. and the U.K, and found that in today’s hyper competitive brand world, more than three-quarters (77%) believe creative output — encompassing all elements of campaigns and content — is more crucial now than ever before, with 69% saying that creative is a top marketing priority in their organization.
The survey revealed a variety of external forces fueling creativity in new ways, and a number of obstacles blocking marketers from unlocking full creative potential. Top findings include:
Creative Output is the New Gold Standard
Marketing leaders are placing increasing value on creative, and there’s expectation this trend will continue.
- More than two-thirds (68%) believe that creative will become more important to their organization in the next 12 months.
- 72% believe that creative output adds value to customers' lives.
But Creative Investment is Falling Short of Proven Worth
Despite the increasing value placed on creative, there is a significant gap in investment.
- More than half (55%) invest 10 to 25% of their total marketing budget on creative, while nearly a fifth (18%) invest less than 10% on creative.
- 41% say they aren’t making the right level of investment in creative tools, systems and technologies.
The Creative Process Has Increased in Complexity
Today’s ecosystem of creative tools is bringing plenty of improvements, but not without new challenges.
- The following elements are ranked as more challenging now (46%) than they were five years ago: managing resources and budgets, maintaining consistency of output, and managing systems and tools.
- Most positive benefits come from the following tools, either by increasing efficiency or improving the creative output: collaboration platforms (54%), photo/video editing tools (54%), generative AI tools (35%).
Keeping Pace with Technological Advances is a Struggle
Marketing leaders are mostly confident in their creative output when compared to competitors, but there are areas where they feel outpaced.
-
Comparing their creative output and processes to competitors:
- 34% believe their creative output is better, and 53% believe it’s on par.
- 45% believe they’re worse at managing a creative process that optimizes for speed, efficiency and flexibility.
In-House Model Gains in Appeal
The landscape of creative management is shifting with more work being brought in-house vs. outsourced to agencies. In-sourcing is mostly seen as a superior process for teams, but outsourcing is used when there is a need to collaborate on high impact creative output.
- 30% have moved more work in-house in the last 12 months, and 31% expect to do the same in the next year.
- 48% say creative strategy is mostly done in-house, while 23% say it’s mostly outsourced.
- 83% say that in-house is better from a cost perspective, while 61% say that outsourcing is better for quality of creative output.
Pool for Top Creative Talent Is Shrinking
There’s concern about a diminishing pool of strong creative talent, underscoring the challenge of securing, managing and retaining talent in a competitive market.
- 47% say the pool of strong talent has gotten smaller.
- 80% feel satisfied with outsourced creative talent and resources; while 74% feel satisfied with in-house creative talent or resources.
“Producing stellar creative output while optimizing for resource efficiency is a massive challenge for every modern marketer today. How brands show up has gotten more competitive, there is a lot of tech to wade through, and the talent pool is narrowing,” said Canva CMO Zach Kitschke. “We’re delighted to work with the MMA team to identify the pain points and opportunities that marketers are facing today, in order to shed light on top-of-mind issues to inform their decision making.”
“While the last few years might seem solely focused on perfecting data, audience development, and targeting to drive outcomes, marketers are also recognizing the need to focus on a second creative revolution,” said MMA Global CEO Greg Stuart. “Marketers face a pivotal moment where embracing AI and the challenge of managing the Brand via what can be thousands of executions will redefine creativity’s role and brand communication, demanding a new and updated focus to managing the creative process.”
Access “The State of Creative Process in Marketing" here.
About Canva
Launched in 2013, Canva is a free online visual communications and collaboration platform with a mission to empower everyone in the world to design. Featuring a simple drag-and-drop user interface and a vast range of templates ranging from presentations, documents, websites, social media graphics, posters, apparel to videos, plus a huge library of fonts, stock photography, illustrations, video footage, and audio clips, anyone can take an idea and create something beautiful.
Canva offers a variety of tools purpose-built for marketers. In recent years, Canva has introduced a number of products and services to help marketers and creatives unlock new levels of creativity, collaborate more effectively, and scale content creation. This includes Canva Teams, the newly introduced Canva Enterprise offering, Brand Kit, and Marketing Work Kits.
About MMA Global
MMA Global is a non-profit trade association dedicated to Architecting the Future of Marketing while Relentlessly Delivering Growth Today. Our Prime Audience is Pioneering Chief Marketers; our Purpose is to enable marketers to drive innovation and enduring business value in an increasingly dynamic and ultra-connected world. The MMA has 800+ corporate members in over three dozen countries and is a truly global organization with offices in 14 countries throughout APAC, EMEA, LATAM, and North America. While the MMA is run and controlled by Marketers, it is the only Marketing-oriented trade body to include all aspects of the ecosystem: Media Companies, Enabling MarTech & AdTech, Platforms, Consultancies, and Agencies. This gives us the perspective to tackle industry issues comprehensively.
Methodology
The study used an online questionnaire. Fieldwork was conducted in May 2024, among large marketers (72% have revenues over $1BN), across a variety of sectors. Respondents were senior marketers (C-Level 32%, EVP/SVP/VP 35%, Other senior 32%).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240616737948/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
